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Nowadays different healthcare policies in OECD countries seem to consider hospital readmissions 
somehow “quality dependent”. Nonetheless, the theoretical literature on the incentives provided by 
payment systems tend to disregard this aspect, which indeed might be relevant in driving providers’ 
behaviour. In this paper we study the incentives for hospitals to provide quality and cost-reducing 
effort under different payment regimes, either a global budgeting or a prospective payment system, 
considering explicitly the role played by financial incentives directly linked to readmissions. As far as 
the specific results about quality are concerned, we find that prospective payment systems do not 
necessarily perform better than retrospective systems if the reimbursement to hospitals is not adjusted 
to take into account specific outcome-based indicators of quality, such as readmissions. More 
specifically, if patients readmitted are fully paid to hospitals, moving from a retrospective to a 
prospective payment systems might even induce a reduction on quality and, in turn, an increase in 
readmission probability. However, if the prospective payment system is adjusted for internalizing this 
counter-incentive, by a different payment for patients readmitted, it could be able to foster a higher 
treatment quality through the competition channel. 
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1. Introduction 
The key tenet of many reforms of the healthcare sector has been to introduce incentives 
for improving efficiency without losing quality of care. For this purpose, in the last decades 
many OECD countries reformed the providers payment system, introducing fairly anywhere 
some form of prospective payment system and reducing the scope for global budgeting 
(Busse et al., 2011), with the aim of increasing the competition in the market and, 
consequently, quality and efficiency. In this setting, prices are usually regulated and, thus, 
providers compete on quality to attract more patients. In particular, the incentive to compete 
for patients should be presumably due to the positive margin (DRG tariff exceeding marginal 
costs) efficient hospitals can enjoy. However, while the propulsive effect on efficiency would 
seem to be confirmed by the data, the empirical findings on hospital quality are ambiguous 
and far from being well-established. 
Although there is some evidence suggesting that competition with fixed prices does not 
erode quality and outcome
1
, the empirical literature concerning the introduction of 
prospective payment system and the effects on quality of care offers a less clear cut picture 
and for most countries it remains limited (Moreno-Serra and Wagstaff, 2010). The majority of 
empirical studies trying to assess these effects are relative to the US and, in particular, they 
look at the impact of the change in Medicare hospital payment system, from a cost plus to a 
prospective per case payment. Early studies compared Medicare patients before and after the 
implementation of per case payment system. In Davis and Rhodes (1988) they reported that 
per case payment reduced hospitalization and length of stay, although mortality and 
readmission rates did not increase. Similarly, Kahn et al. (1990) documented that length of 
stay decreased by 24%, although 180-day risk-adjusted mortality and readmission rates 
remained unchanged. Conversely, in a large influence study Cutler (1995) examined mortality 
                                                          
1 There is less theoretical and empirical consensus about the effect of competition on quality when prices are market determined. For 
example, Volpp et al. (2003) and Propper et al. (2004) find that competition decreases quality; conversely, Sari (2002) finds the opposite 
effect. For a survey see also Gaynor and Town (2011). 
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and readmission rates of Medicare patients and found that while 1-year mortality rate 
remained unchanged, readmission rate increased. More recently, Glickman et al. (2007) 
studied heart attack care processes in 54 hospitals from 2003 to 2006, without finding 
significant incremental improvement in quality of care or outcomes for acute myocardial 
infarction attributable to specific changes of hospital financing system. Similarly, Jha et al. 
(2010) concentrated their attention on 251 hospitals that collected data on 33 quality measures 
for 3 conditions (heart attack, pneumonia and heart failure), finding very low improvements 
in mortality rates attributable to a specific change in the payment system. 
In the last decade similar analyses have been conducted also in other countries. Quality 
as reported by patients’ experience has been considered by Hagen et al. (2006), who analyzed 
the effects of a reimbursement reform in Norway, aimed at replacing a capitation-based block 
grant system with an activity-based system. In particular, they found that patient satisfaction 
increased after the reform probably for the lower waiting times induced by the introduction of 
activity-based financing. Farrar et al. (2009) studied the effects of the change from global 
budgets to case payments in English NHS, with the aim to examine whether the introduction 
of payment by results was associated with changes in key outcome variables measuring 
quality of care, volume and costs. Concerning quality of care, mortality measures after hip 
fractures did not change significantly after the introduction of the new system. Conversely, 
Berta et al. (2010) carried out a study for the Lombardy Region, finding that financial 
incentives do affect the pattern of discharges. 
Hospital readmissions and their preventability have been the subject of a large debate 
since the introduction of per case payment. Even if some readmissions cannot be avoided, low 
readmission rates are among the outcome-based indicators often used as a proxy measure for 
a good inpatient care quality (e.g. Ashton et al., 1997, Cavalieri et al., 2013). In particular, the 
idea behind outcome-based indicators is that, if appropriate risk-adjustment is made for 
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patient case-mix and other external factors, differences in readmission rates (or in hospital 
mortality) are likely to be driven by differences in the unobservable hospital quality.  
Moreover, a considerable amount of empirical studies used readmission rates also to evaluate 
other important issues in health research as the impact of new technologies (Xian et al., 2011) 
and the impact of specific new policy changes (Evans et al., 2008). Therefore, moving from 
this argument that hospital readmissions might be somehow “quality dependent”, in recent 
years there has been a large interest in introducing incentives for hospitals to avoid post-
discharge complications potentially preventable. 
In the US a large effort has been put on introducing arrangements of “bundled 
payments” across multiple providers, so as to avoid the lack of incentives to coordinate 
healthcare provision, considered as one the major causes of high readmission rates for 
Medicare beneficiaries (MEDPAC, 2008; McCellan, 2011). Moreover, the Hospital 
Readmission Reduction Program (HRRP), designed with the objective of reducing 
readmissions by aligning payment with outcome, introduced a system of penalty in Medicare 
base reimbursement system for hospitals underperforming in a selected number of 30-day 
risk-adjusted readmission rates (Foster and Harkness, 2010, Adashi and Kocher, 2011). 
Likewise, in other institutional settings we can find incentives to prevent high readmission 
rates in prospective per case payment. For instance, in Germany hospitals have a clear 
incentive to avoid readmissions because they will not receive additional reimbursement for 
cases readmitted within 30 days of the initial admission (Geissler et al., 2011). A similar rule 
has been recently introduced in English NHS (Department of Health, 2011), where hospital 
payments stop for all emergency admissions occurring within 30 days of a previous discharge. 
Despite this explicit consideration in the healthcare policy design, the theoretical 
literature on the effects of hospital payment systems tend to disregard this aspect (e.g. Ma, 
1994, Karlsson, 2007, Brekke et al., 2012, 2013), which indeed might be relevant in driving 
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providers’ behaviour. Moreover, for policy design purpose it would be extremely interesting 
to consider the potential role of financial incentives associated with specific outcome-based 
indicators, especially since treatment quality is often unobservable for the regulator. In this 
paper we study the incentives for hospitals to provide quality and cost-reducing effort under 
different payment regimes, either a global budgeting or a prospective payment system, 
considering explicitly the role played by financial incentives directly linked to readmissions. 
While this feature of the payment system would not seem particularly important for inducing 
cost-reducing effort
2
, this turns out to be particularly crucial in driving the provision of 
quality in the treatment. We consider the analysis of the effects of different reimbursement 
systems within a context characterized by the existence of non-financial incentives for 
providers, considered in the literature especially relevant in the healthcare market (e.g. 
Viggiano et al., 2007, Makris and Siciliani, 2013). 
As far as the specific results about the incentives to provide quality are concerned, we 
find that prospective payment systems (PPS) do not necessarily perform better than 
retrospective systems (RPS) if the reimbursement to hospitals is not adjusted to take into 
account specific measures of quality, such as readmissions. More specifically, if patients 
readmitted are fully paid to hospitals, moving from a global budgeting to a prospective 
payment system might even induce a reduction on quality and, in turn, an increase in 
readmission probability. However, if the prospective payment system is adjusted for 
internalizing this counter-incentive, by a different payment for patients readmitted, it could be 
able to foster a higher hospital quality through the competition channel. 
Considering that actual payment systems rarely (or only recently) provide explicitly for 
a different payment for patients readmitted, this paper might explain the ambiguity found in 
previous studies concerning the impact of the introduction of PPS on quality. On the other 
                                                          
2 Indeed, omitting cost-reducing effort would not have changed much our main results; nonetheless, we decided to maintain it in the analysis 
for two main reasons. First, it allows us to appreciate also the role of prospective payment system in promoting higher efficiency respect to 
retrospective system. Second, it makes the paper more comparable to the recent literature on hospital financing systems (e.g. Brekke et al., 
2012, 2013). 
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hand, it underlines that if PPS is well-designed (by a different readmission policy), the 
introduction of the new system could be able to promote a higher quality. To this extent, our 
study contributes to the literature on hospital payment systems by introducing this specific 
feature in the evaluation of the financing system and, in particular, by shedding more light on 
the design of optimal readmission payment to induce higher hospital quality. 
The remainder of this study is organized as follows. The setup of the model is laid out 
in section 2. Section 3 develops the equilibrium results and their comparison across the 
different financing systems. Section 4 contains a social welfare analysis and, finally, section 5 
provides with some concluding remarks. 
 
2. Model 
In this section we introduce the main structure of the model. In line with the previous 
literature on hospital competition (e.g. Beitia, 2003, Brekke et al., 2008, 2010), the analysis of 
providers’ behaviour is conducted in the framework of the Hotelling spatial competition 
(Hotelling, 1929), where we study a market for medical treatment with two hospitals located 
at the either end of the unit line S = [0, 1]. We consider providers location as exogenously 
given, which indeed is somewhat reasonable for the case of healthcare providers. On the line 
segment S there is a uniform distribution of patients, with density normalised to 1, each 
demanding only one medical treatment. As fairly realistic for this market, patients do not pay 
for the treatment they get, rather they mind only for the quality of those. Assuming full 
market coverage, that is each patient does not have an attractive outside option, all patients 
simply choose which hospital to demand from. The utility of a patient located at     and 
receiving treatment from hospital i, located at zi, is given by             
                                                                                                                 (1) 
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where   is the gross valuation from medical treatment,        is the treatment quality at 
hospital i,   is the parameter measuring the marginal utility of quality and   is the 
transportation cost parameter
3
. The lower bound   represents the lowest treatment quality 
hospitals are allowed to offer, implying that if       then i might lose his licence. Without 
loss of generality, we set    . Moreover, as standard in this literature (e.g. Brekke et al. 
2012) we normalise the marginal utility of treatment quality to one,    , implying that now 
  can be interpreted as the marginal disutility of travelling relative to treatment quality. 
The patient who is indifferent between provider i and provider j, located respectively at 
       and       , can be implicitly characterised by his location  
     
       –    
           –         
                                                                                (2) 
yielding, given the assumption of uniform patients distribution with density 1, the demand for 
hospital i  
  
    
 
 
   
      
  
                                                                                                              (3) 
On the other hand, the demand for hospital j is simply the complement to 1, that is 
  
          
    
 
 
   
      
  
                                                                                          (4) 
Therefore, if hospitals offer the same treatment quality they exactly halve the market. 
Differently, the hospital with a higher treatment quality gets a market share more than half. 
Finally, the extent to which the difference in treatment quality affects the hospital market 
share strictly depends on the marginal disutility of travelling relative to quality  . In 
particular, a high   implies that the disutility of travelling is relatively more important for 
patients than quality, making demand less responsive to change in quality.  
Hospitals are financed by a third-party payer potentially either retrospectively or 
prospectively. Since we specify both cases later in the paper, here we introduce the general 
                                                          
3 There is a wide empirical evidence showing that the main predictors of hospital choice by patients are distance to hospitals and quality of 
treatment. For instance, the empirical studies by Tay (2003), Shen (2003), Howard (2006) and Varkevisser et al. (2012) show quite 
consistently that both predictors are strongly significant, with a relative weight depending on the case under analysis.  
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form of the objective function. As mentioned in the introduction, despite the empirical 
relevance of readmissions, in the existing literature the explicit role of patients readmission is 
usually neglected. Differently, in this paper we attach much importance on the way in which 
readmissions affect the incentive provided by different hospitals payment systems. Therefore, 
we consider explicitly revenue and cost of readmissions in the hospital profit. Moreover, as 
discussed by different papers in the literature (e.g. Ellis, 1998, Harrison and Lybecker, 2005, 
Brekke et al., 2011), despite financial incentives actually receive the lion’s share of the 
interest, it is recognized that non-financial incentives might be relevant in the health care 
market where the relationship between patient and provider is essentially based on trust. Thus, 
we consider these non-financial motivations as relevant in driving providers’ behaviour. 
The cost of medical treatments is given by the cost function        , assumed 
increasing and convex both in output and quality, plus some fixed cost F  
          
 
 
         
 
 
                                                                                                  (5) 
While the marginal cost for quality    is equal for both hospitals, the treatment marginal cost 
   can be reduced by each hospital exerting a cost-reducing effort  , which to some extent 
should allow us to capture the incentive provided by different payment systems on cost-
efficiency. In particular, a positive cost-reducing effort implies a reduction on cost given by 
         . Nonetheless, whenever hospitals exert a positive cost-reducing effort, they incur 
a managerial disutility 
 
 
   . Furthermore, we consider also a potential managerial disutility 
induced by a higher quality 
 
 
   , aiming to capture the fact that the quality of medical 
treatment is not only a money matter but also a diligence matter. 
Each patient treated by hospitals has a positive probability of being readmitted, 
governed by a certain severity index h. However, moving from the argument that hospital 
readmissions might be somehow “quality dependent”, we consider also that the readmission 
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probability can be consistently reduced by a high quality treatment. In particular, the 
probability of being readmitted is assumed to be given by  
                                                                                                                         (6) 
where   is the parameter governing the impact of quality on the readmission probability4.  
Therefore, knowing that     is the lowest hospital quality standard to be licensed, the 
severity index h represents the upper bound readmission probability for each patient
5
. 
Whenever a patient is readmitted hospitals incur a readmission cost R, thought to be 
somewhat smaller than the marginal cost at the initial admission. In particular, this 
assumption on R should capture the idea that patients readmitted usually do not need to repeat 
all medical procedures performed at the first admission. On the other hand, contingent on the 
payment system, hospitals receive a payment, which in a prospective system is strictly related 
to the parameter          . In particular, when     hospitals receive a full per-treatment 
price as for the first admission, whereas when     hospitals receive nothing and, thus, they 
suffer all the readmission cost. Therefore, the parameter   can be interpreted as the degree of 
risk sharing in the system (between providers and third-party payer) relative to readmission. 
It is evident that, whenever the risk of readmission is discharged entirely to provider 
(     ), there is an incentive for hospitals to avoid somehow to readmit patients. 
Nonetheless, in the first part of the paper we assume that hospitals are not able to make 
rationing. Even if this might be somewhat unreasonable, this allows us to highlight the main 
role played by the readmission policy in driving providers’ behaviour and, in turn, the 
equilibrium quality under PPS. Then, in the final part of the paper we discuss explicitly the 
occurrence of hospitals rationing. 
                                                          
4 Evidently, there is a propulsive role for quality in reducing readmission probability as long as      , which we consider reasonable in the 
majority of medical branches. On the other hand, our specification (6) explicitly rules out non-negative probabilities. 
5 To some extent, there may potentially be other plausible specifications different from (6) describing the readmission probability. We 
decided to adopt (6) because on the one hand it allows algebraically to derive the model implications, on the other hand it has a clear 
interpretation of both the severity index and the readmission “quality dependence”. Nonetheless, we tried to derive the equilibrium of the 
model with other specifications and, indeed, as long as the specification allows us to handle it, we found exactly the same implications.     
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Finally, we include explicitly the non-financial motivation of provider management 
        , with the parameter       governing its relative weight in the provider objective 
function. The main idea behind this non-financial part is that offering a high quality medical 
treatment gives hospital staff a high social and professional status which, in turn, gives them a 
higher non-monetary utility. Therefore, the assumptions we consider reasonable to make are 
that       ,         and          . In particular, for the sake of simplicity we assume 
that the provider non-financial motivation is given by
6
  
                                                                                                                                   (7) 
Therefore, the objective function of hospital i is assumed to be given by                
            
       
                          
            
    
 
 
   
   
 
 
   
        (8)  
where T is a potential lump-sum transfer and p is a prospectively regulated price per-
treatment, differentiated according to the payment system under consideration. 
In what follows we will consider the simultaneous game where each hospital chooses 
independently his treatment quality   and his cost-reducing effort  , in order to maximise his 
objective function. In particular, we will firstly derive the hospital reaction-curves to study the 
kind of strategic interaction is induced by different payment systems and, then, we will look 
for the symmetric Nash equilibrium. Finally, we will move towards a welfare analysis to 
derive the main implication of the model in terms of different payment systems and, in 
particular, in terms of hospital readmission policy. 
    
3. Nash equilibrium 
In the general formulation, the hospital i’s maximization problem is given by 
                                                          
6 The standard way in the literature to introduce the non-financial motivation is to imagine that providers management receive a positive 
utility from the consumer surplus. However, in that specification even providing a very low quality medical treatment (remember that    ) 
gives a positive non-financial utility, which is something we consider unreasonable. Differently, in (7) hospitals management receive a 
positive non-financial utility only providing at least a quality higher than the license standard, emphasizing the interpretation of the non-
financial utility as a higher social and professional status given by a high quality health services. Nonetheless, it can be easily found that the 
two different interpretations produce indeed the same model implications.   
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with T and p depending on the hospital payment system under consideration
7
. The solution to 
this maximization problem is given by the two FOC 
   
   
                                                                                                                                          (9) 
   
   
                                                                                                                                        (10) 
In the following, we will consider two standard hospital payment systems: retrospective 
payment system and prospective payment system
8
. Later on, we will show that the 
specification of the risk sharing readmission policy ( ) has crucial implications with respect 
to the comparison of the two payment systems. 
 
3.1 Retrospective payment system 
In a basic retrospective payment system hospitals do not receive a predetermined price 
for any patient they treat, rather they are fully reimbursed according to how much cost they 
already faced. Therefore, the hospital revenue is given only by a retrospective lump-sum 
transfer, that is    
                                                                                                                                          (11) 
      
  
 
    
  
 
   
 
 
   
                    
                                                                (12) 
Inserting (11) and (12) in the hospital objective function (8) yields 
  
            
   
 
 
   
   
 
 
   
                                                                                               (13) 
Applying the FOC to the objective function (13) we have  
                                                          
7 Notice that we are explicitly ruling out the existence of corner solution in the readmission probabilities (that is,               ); thus, 
our subsequent analysis is valid only for those medical branches where readmissions are relevant. After all, it would not make sense to 
discuss on the effect of readmission policy and its optimal design in those medical branches where readmissions are somewhat insignificant.  
8 Indeed, there are at least two different general payment systems ascribed to prospective, that is the prospective budget allocation (e.g. 
Austria, Portugal, Spain) and the prospective case payment (e.g. in England, France, Germany, Italy, the US). However, as usual in this 
literature we consider the prospective payment system in the meaning of the prospective case payment.  
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                                                                                                 (14) 
  
                                                                                                                                         (15) 
From the reaction curve (14) we can see that in a retrospective payment system hospitals act 
as strategic substitute in quality
9
. To grasp the intuition for this result we should consider that 
in a retrospective payment system there are not “financial” incentives to increase quality for 
attracting more patients; rather, providers’ behaviour is more driven by the “non-financial 
motivation”, as (13) clearly shows. In particular, when hospital j increases quality, fewer 
patients demand medical treatment from hospital i, which in turn reduces the marginal 
(altruistic) benefit from improving quality. Moreover, when the quality of j is high, then 
hospital i might find too costly in terms of managerial disutility to keep up with j. Thus, once 
behind the competitor hospital i might even find optimal to reduce quality. 
Similarly, from (15) we can see that in a retrospective payment system there is no scope 
for exerting a positive cost-reducing effort. Again, the intuition is that in such kind of 
payment system providers’ behaviour is more driven by the non-financial motivation, which 
has to do with the quality of medical treatment but not much with the cost-efficiency. 
Finally, solving for the symmetric Nash equilibrium we find  
      
  
      
                                                                                                                           (16) 
                                                                                                                                          (17) 
Analysing the comparative statics properties of (16), they are quite reasonable and intuitive. 
In particular, a higher weight of the non-financial motivation in the provider objective 
function     leads to a higher equilibrium quality. On the other hand, a higher marginal 
managerial disutility of quality     and a higher marginal disutility of travelling relative to 
                                                          
9 Notice that the SOC for this maximization problem reads 
 
   
  
   
   
 
 
                                 
 
Not surprisingly when the non-financial utility is significantly high, in a payment system where all costs are reimbursed, there is an unlimited 
incentive for increasing quality. Nonetheless, we prefer to rule out this case on the one hand because it is somewhat unreasonable, on the 
other hand because it eliminates any scope for the analysis of the incentives provided by the different payment systems. Indeed, in that case 
financial incentives provided by payment systems become less relevant. 
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treatment quality    , implying a lower demand responsiveness to change in quality, lead to a 
lower equilibrium quality
10
. 
 
3.2 Prospective payment system 
Differently, in a prospective payment system hospitals receive a prospectively regulated 
price for any patient they treat, plus potentially some fixed lump-sum transfer aiming often to 
cover the fixed cost
11
. Therefore, in this case the hospital revenue is given by  
                                                                                                                                          (18) 
                                                                                                                                          (19) 
Inserting (18) and (19) in the hospital objective function (8) yields 
  
            
       
                          
           
   
 
 
   
   
 
 
   
         (20) 
Differently from (13), we notice that in a prospective system, not only the “non-financial”, 
but also the “financial” part of provider objective function depends on the level of medical 
treatment quality and cost-reducing effort. Using the FOC with the objective function (20) we 
have 
  
     
    
 
 
      –                
 
  
                         
     
 
  
             
 
  
                         
                               (21) 
  
     
 
 
 
  
      
  
 
 
  
                                                                                                                    (22) 
Looking at the reaction curve (21), we can see that in a prospective payment system, as 
long as the weight of the non-financial motivation is not so high, hospitals act as strategic 
complement in quality
12
. The main intuition is that in a prospective payment system hospitals 
                                                          
10 From (16) we obtain 
 
    
  
  
    
         
   ,             
    
  
   
    
        
              and             
    
  
   
  
        
  . 
 
11 For instance, in England only the 60% of hospitals revenue is financed according to the DRG-based case payment, while the remaining is 
financed by global budget and other additional payments. Furthermore, a fairly similar picture is present in France, Germany and other 
European countries (see Cots et al., 2011).  
12 In particular, the condition on the weight of the non-financial motivation, implying that hospitals act as strategic complement, is simply 
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revenue strictly depends on the actual number of patients they treat. Therefore, this gives 
providers a consistent financial incentive to keep up with the level of treatment quality to 
avoid losing demand, which indeed represents the essential stimulus provided by competition 
in a market with regulated price. 
Similarly, from (22) we see that the presence of a fixed payment for patient treated also 
provides the incentive for hospitals to exert a positive cost-reducing effort, in order to reduce 
the marginal cost and, in turn, to increase the profit margin. 
Then, applying symmetry to (21) and (22) the candidate Nash equilibrium are 
      
    
 
 
      –               
                      
                                                                                          (23) 
      
 
  
                                                                                                                                  (24) 
Differently from the previous case, the comparative statics of the equilibrium quality (23) are 
quite interesting. In particular, we can notice from (25) that, as long as the degree of risk 
sharing ( ) is sufficiently high, a higher fixed payment ( ) might even reduce the equilibrium 
quality. 
    
  
   
  –                                       
 
 
    –              
                        
  
             
            
      (25) 
Likewise, from (26) we see that, as long as the impact of quality on the readmission 
probability (   is sufficiently high, a higher degree of risk sharing ( ) reduces the equilibrium 
quality
13
. This constitutes the first main result of the paper. 
    
  
    
                                   
 
 
    –                
                         
  
             
           
       (26) 
 
                                                                                                                                                                                     
     
 
  
                              
   
  
   
   ,  
 
which we think as being fairly reasonable in our context. 
13 More specifically, a sufficient condition for being (26) negative relates   with the degree of competition in the market, requiring that the 
impact of quality in the readmission probability has to be higher when the competition in the market is higher     
 
 
. This is not surprising 
because the two parameters   and   determine respectively the marginal expected cost (in terms of lower readmissions) and the marginal 
expected benefit (in terms of higher demand) of increasing quality. Therefore, the extent to which   should be high for being (26) negative 
has to be necessarily related to the degree of competition in the healthcare market 
 
 
. 
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Proposition 1. As long as the impact of quality on the readmission probability (   is 
sufficiently high, in a PPS the equilibrium quality is strictly decreasing with the risk sharing 
relative to readmission  . 
 
The main intuition for this result is that when patients readmitted are costly for 
hospitals, that is   is low, and the probability of readmission depends on the quality of 
treatment, there is a clear incentive in PPS for increasing quality to reduce readmissions. 
Conversely, when hospitals receive a higher payment for patients readmitted, the higher 
revenue increases the attractiveness of readmissions and, to the limit, there might be a scope 
for reducing quality to increase readmissions and, in turn, the revenue. On the other hand, 
when the readmission probability depends only barely on quality, there are no reasons 
concerning the amount of patients readmitted affecting the choice of quality. Rather, in this 
case a higher   increases the expected benefit of each patients and, ceteris paribus, the 
hospital’s incentives for quality provision. 
To some extent, since the majority of the actual PPS do not provide explicitly for a 
readmission policy, implying that hospitals receive a full payment for patients readmitted, the 
Proposition 1 might be extremely useful in offering an easy instrument to induce a higher 
quality of medical treatment. 
Finally, the other comparative statics of (23) are more expected. In particular, a higher 
weight of the non-financial motivation ( ) and a higher competition ( ) lead to a higher 
equilibrium quality. On the other hand, a higher marginal managerial disutility of quality ( ) 
and higher marginal costs ( ) and (c) lead to a lower equilibrium quality14. Moreover, from 
                                                          
14 From (23) we get the following 
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     –                
                       
              and            
    
  
    
 
                        
  . 
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(24) we see that a higher marginal managerial disutility of effort ( ) reduces the equilibrium 
cost-reducing effort
15
. 
 
3.3 Payment systems comparison 
In this section we compare the equilibrium values of the two payment systems. From 
(27) we can see that the comparison of the equilibrium cost-reducing effort between RPS and 
PPS highlights unambiguously the advantage of PPS in terms of cost-efficiency.    
          
 
  
                                                                                                                 (27) 
The main intuition is that in a payment system with price established prospectively, hospitals 
enjoy entirely the increased profit margin associated with a reduction in the marginal cost, 
since the greater hospital efficiency does not imply a reduction in the revenue. Differently, in 
a system where reimbursement is established retrospectively, there is not any incentive for 
hospitals in reducing costs, since all the reduction is enjoyed by the third-party payer. 
Differently, from (28) we can see that the comparison of the equilibrium quality 
between RPS and PPS is quite ambiguous and, indeed, strictly depends on the parameter 
values. Moreover, since the impact of the fixed price on the equilibrium quality in PPS is also 
ambiguous (25), even an increase of   does not imply unconditionally a higher equilibrium 
quality in PPS respect to RPS. Therefore, the propulsive role of competition induced by a 
prospective payment system might not be enough to induce a higher treatment quality. 
      
  
      
   
    
 
 
                      
         –            
                                                                 (28) 
However, since a higher degree of risk sharing ( ) decreases the equilibrium quality in PPS 
when   is sufficiently high, whereas has not impact on RPS, we can certainly maintain that 
                                                          
15 Similarly, from (24) we have that  
    
  
   
 
   
  .  
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should exist a potential role for PPS in inducing a higher equilibrium quality, this would 
certainly be curbed by a higher  . 
To shed more light on this comparison, in Figure 1 we show the reaction curves and, in 
turn, the equilibrium quality under RPS and PPS resulting by a simulation with the same 
parameter values
16
. In particular, since the PPS often do not provide explicitly for a 
readmission policy implying a different payment, we start our numerical exercise considering 
a full payment for patients readmitted (     ). 
 
  
Fig. 1. Reaction curves and equilibrium quality under RPS and PPS 
 
As we can notice, whereas in RPS the presence of competitors in the healthcare market 
induces a reduction in the equilibrium quality, PPS is indeed able to convert the kind of 
strategic interaction between providers and, therefore, there seems to be a potential role for 
competition in stimulating a higher equilibrium quality. However, as Figure 1 shows this 
propulsive role might not be enough to guarantee unconditionally a higher equilibrium quality 
                                                          
16 The numerical exercise has been conducted with the following parameters: 
 
                                                        . 
 
Notice that the condition for being (26) negative has been matched only with the equality (that is,     
 
 
), so that the effect of the different 
readmission policies in this simulation is just at the minimum amount. In fact, from (26) we know that the higher is  , the higher is the 
negative effect of   on equilibrium quality. More information on the algorithm are promptly available under request by authors. 
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in the market and, in particular, the presence of a full readmission payment might frustrate its 
propulsive effect
17
. This result is summarized in the proposition below. 
 
Proposition 2. As long as the impact of quality in the readmission probabilities is 
sufficiently high and hospitals receive a full payment for patients readmitted, a PPS might 
even induce a reduction in quality and, in turn, an increase in readmission probability. 
 
To some extent, the content of Proposition 2 could explain the large empirical evidence 
concerning the impact of the introduction of PPS on quality. As we noted in the introduction 
of the paper, while the evidence on cost-efficiency would seem to highlight the advantage of 
PPS, the empirical findings on hospital quality are still quite ambiguous. Indeed, considering 
that the actual PPS often do not provide explicitly for a readmission policy implying a 
different payment for patients readmitted (     ), Figure 1 might represent exactly the 
ambiguity we find in the data. 
On the other hand, Proposition 2 gives rise to the fair question if such limitation of the 
effect of competition might be internalized in the payment system by a different readmission 
policy. Therefore, in Figure 2 we report the PPS equilibrium quality, along with the 
associated readmission rate, under different readmission policies. We can see that already a 
limited reduction in the readmission payment is enough to allow the propulsive role of 
competition to do more successfully the job. More generally, Figure 2 shows that the bigger is 
the reduction in the readmission payment, the higher is the equilibrium quality and, in turn, 
the lower is the readmission rate
18
. This constitutes the content of the next proposition. 
                                                          
17 In particular, in the numerical simulation reported in Figure 1 the equilibrium qualities in the two payment systems are quite close: 
 
                      . 
18 More precisely, the equilibrium qualities showed in Figure 2 are 
 
                                 and                               , 
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Fig. 2. PPS quality and readmission rate under different readmission policies 
 
Proposition 3. The propulsive role of competition induced by a PPS should be more 
successful in driving a higher equilibrium quality and, in turn, lower readmission rate in 
those systems providing for a lower degree of risk sharing relative to readmission. 
 
The aim of this comparison has been to identify the different incentives given by the 
two payment systems to providers’ behaviour. In particular, we established that, as long as 
hospitals receive a high payment for patients readmitted, the propulsive role of competition 
induced by PPS might not be enough to ensure a higher equilibrium quality respect to RPS. 
On the other hand, PPS should be successful in driving a higher equilibrium quality whenever 
the readmission policy provides for a low degree of risk sharing. 
However, at this stage nothing ensures neither that the equilibrium quality induced by 
PPS would be indeed the first-best quality, nor that the first-best quality can be really 
achieved under PPS by some optimal policy instrument regulation. Therefore, in the next 
section we move to the welfare analysis in order to answer to these crucial questions. In 
particular, in what follows we will try to emphasize mainly the role of the optimal 
                                                                                                                                                                                     
implying a quality increase respectively of 10% and 20% respect to the equilibrium quality with full readmission payment and, all the more 
so (see footnote 17), respect to the equilibrium quality under retrospective payment system. 
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readmission policy as an instrument in the context of a prospective payment system to induce 
the first-best quality. 
 
4. Social Welfare 
Following the previous literature, we define social welfare as the sum of consumer 
utility net of monetary costs as well as disutility costs. In addition, in the most general 
formulation we include the non-financial utility of providers, which clearly disappears 
considering      19. Therefore, the social welfare function is given by20 
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                                                            (29) 
 
4.1 Optimal readmission policy 
We start out by deriving the first-best cost-reducing efforts and qualities. Maximising 
(29) with respect to cost-reducing efforts and qualities yields  
           
                   
 
  
                                                                                 (30) 
and 
           
                   
         
       
                                                                    (31) 
                                                          
19 Indeed, there is a heated discussion in the literature concerning the inclusion of the altruistic (or non-financial) component in the social 
welfare function as this would lead to double-counting (see e.g. Chalkley and Malcomson, 1998). Nonetheless, in our general formulation we 
decided to include this component, knowing that it clearly disappears considering      . 
20 Notice that in (29) we are implicitly assuming that patients readmitted, after being re-treated, enjoy the same utility of those patients not 
readmitted. Indeed, considering a double cost for patients readmitted would lead to the following more complicated “social welfare function” 
 
                                    
  
 
 
                                        
 
  
  + ...  
 
Nonetheless, since this welfare function would produce exactly the same implications in terms of policy than (29), for the sake of simplicity 
we decided to neglect the double cost issue, knowing that the inclusion of it does not enrich significantly the picture. Indeed, this allowed us 
to keep the results of welfare analysis as simple as possible, without changing the main policy implications. 
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Looking at (30), we see that the first-best cost-reducing effort depends negatively only 
on the marginal disutility of effort ( ). Concerning the first-best quality (31), on the one hand 
higher monetary ( ) and disutility costs ( ) reduce it; on the other hand, higher provider non-
financial utility ( ) and expected readmission costs (Rh) lead to a higher first-best quality. 
Furthermore, the comparison between (24) and (30) reveals that         , a standard 
result in the multi-task agency literature (e.g. Chalkley and Malcomson, 1998). 
  
Proposition 4. Regardless of the readmission policy, a PPS with regulated price is able 
to induce the first-best cost-efficiency. 
 
Differently, the comparison between (23) and (31) reveals that the equilibrium quality 
under PPS is not generally equal to the first-best quality, that is         . Nonetheless, from 
(23) we know that the regulator has two policy instruments to induce the first-best quality 
level, the fixed price (p) and the degree of risk sharing relative to readmission ( ). Indeed, the 
more usual regulation considered in the literature is to choose the price to induce the 
equilibrium quality equal to the first-best quality. Nonetheless, as expected the addition of the 
readmission policy as an instrument on regulator’s hands, adds some degree of freedom to the 
optimal policy design. 
Looking at the first instrument, the optimal price regulation    is implicitly 
characterized by 
                  
yielding 
        
 
 
              
         
       
 –   
          
       
          
  –    
          
       
          
                                                  (32) 
Thus, the first-best quality can be implemented in PPS by the optimal price regulation. 
However, notice that such optimal price depends on the degree of risk sharing relative to 
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readmission. Therefore, the regulator does not have a unique optimal price to induce the first-
best quality, but in principle he has a bundle of optimal policies made by all possible couples 
(   ) given by (32). Interestingly, from (33) we can see that, as long as the impact of quality 
on the readmission probability (θ) is sufficiently high, the optimal price inducing the first-best 
quality has to be higher when the degree of risk sharing is higher. This central result is 
resumed in Proposition 5.   
      
  
         
  
          
       
          
  –    
          
       
          
                                                                         (33) 
 
Proposition 5. As long as the impact of quality on the readmission probability (   is 
sufficiently high, the optimal price inducing the first-best quality has to be higher in those 
systems with a higher degree of risk sharing relative to readmission. 
 
The intuition behind this result can be appreciated by the combination of (25) and (26). 
From the former we know that an increase in price ( ) does not induce unconditionally a 
higher equilibrium quality (   ) and, in particular, as long as the degree of risk sharing ( ) is 
consistently greater than zero, a higher fixed payment might even lead to a reduction in the 
equilibrium quality. From the latter we know that, regardless of the price, a higher degree of 
risk sharing ( ) reduces the equilibrium quality (   ). Therefore, a higher degree of risk 
sharing not only reduces per se the equilibrium quality, but also reduces the marginal effect 
of the per-treatment price. On the contrary, a lower degree of risk sharing not only allows to 
the price instrument to do more effectively its job, but also helps to induce a higher quality 
through its own effect on it. 
Hence, the regulator not only can induce the first-best quality, but can also select a 
couple of policy instruments trying to reduce the monetary cost of the policy. Since funding 
healthcare services requires always some form of distortionary taxation (e.g. Brekke et al. 
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2008, Siciliani et al., 2013), it would be certainly valuable for the regulator being able to 
reduce the costs of regulation. Therefore, to the extent that all optimal policies in the bundle 
(   ) given by (32) are able to induce first-best quality in the healthcare market, the optimal 
policy regulation is that couple of policy instruments (   ) in the bundle minimising the cost 
of public funds. Thus, conditional on the hospitals inability to rationing, the optimal policy 
regulation is simply given by 
                                                                                                                                            (34) 
and 
            
 
 
                 
           
       
      
           
       
                 (35) 
 
Proposition 6. The optimal policy regulation is that couple of policy instruments (   ) 
such that the degree of risk sharing is equal to zero (34) and the optimal price is accordingly 
set as (35). 
 
The main intuition for being (34) and (35) the optimal policy is that with a null risk 
sharing, that is      , readmissions become extremely costly for hospitals and, thus, there is 
the strongest possible incentive for increasing quality to reduce readmissions. 
Correspondently, the optimal price given by (35) represents indeed the lowest possible price 
still able to induce the first-best quality in the market. 
In principle, the result contained in Proposition 6 might offer to healthcare policy 
makers a valid instrument not only to induce the first-best quality in the market, but also to 
implement the policy in the cheapest way. To some extent, the feature of the optimal policy to 
minimise the cost of public funds should be extremely important, as it is well-recognised that 
there is a positive cost from collecting money through some form of distortionary taxation in 
the society. Moreover, even in the case policy makers would not be able to implement such 
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policy, the principle underpinning the result in Proposition 5 is still valid: that is, the lower is 
the degree of risk sharing, the lower is the price needed to induce the first-best quality. 
 
4.2 Policy implementation 
Although the optimal policy regulation is in principle implementable, there are different 
reasons why it might not be optimal in practice. First, notice that all normative results have 
been derived conditional on the hospitals inability to rationing. However, as we already 
observed this assumption might be somewhat unreasonable, since hospitals do have 
instruments to try to put in practice some form of rationing. Therefore, the readmission policy 
(      ) might be extremely risky, inducing hospitals to avoid somehow to readmit those 
patients requiring a new treatment. Moreover, for political and economic reasons, it might be 
difficult for the government to stand by such readmission policy. Last but not least, in those 
countries using PPS the per-treatment price is usually set according to the treatment average 
cost and, indeed, it might be extremely difficult to implement all calculations required by the 
optimal price (35). 
In those plausible cases where one or more of these conditions are significant, that 
readmission policy might not be feasible or optimal. Therefore, one should try to find some 
policy design feasible and easy to implement, but still able to produce the required effect to 
induce the first-best quality. Indeed, the results of this paper would seem to suggest a 
plausible route. 
The principle underpinning our main results is that the readmission policy does 
influence providers’ behaviour on quality by offering a revenue (    
 
 
) or imposing a cost 
(    
 
 
). In particular, we found that a lower degree of risk sharing not only reduces the 
equilibrium quality, but also reduces the optimal price needed to induce the first-best quality. 
Therefore, a fairly reasonable readmission policy might be   
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                                                                                                                                      (36) 
On the one hand, this readmission policy does eliminate the economic attractiveness of 
readmissions induced by a full payment (     ); on the other hand, it does eliminate the 
scope for hospitals to make rationing induced by the optimal readmission policy (      ). 
Finally, it should be both politically and economically sustainable for government and 
healthcare providers. 
Looking at the price, notice that the optimal price (32) implied by (36) would be 
         
 
 
        
 
 
                 
           
       
                                              (37) 
Nonetheless, the implementation of (37) still would require different calculations which, 
indeed, might be difficult to make. Therefore, for the sake of simplicity, a fairly reasonable 
alternative might be   
         
 
 
        
 
 
                                                                                              (38)  
On the one hand, respect to the standard average cost-based rule, the implementation of (38) 
should be extremely simple, requiring just the calculation of the average readmission costs 
(Rhθ), which indeed have an empirical counterpart. On the other hand, respect to the 
theoretical optimal price (37), we are neglecting a bit adding (  ) and a bit subtracting (  ), 
which might somehow compensate and, thus, reduce the extent of the approximation, with the 
crucial advantage of making the implementation extremely easier. 
To resume, a reasonable and very easy to implement policy regulation could be 
     
 
 
   
 
 
 
     
                                                                                                                     (39) 
and 
         
 
 
        
 
 
                                                                                              (40)  
More generally, we have seen from Figure 2 that even a reduction of   different from 
(34) or (39) should be able to produce a significant effect in terms of higher quality respect to 
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the equilibrium quality with full readmission payment. Thus, those countries providing a full 
payment for patients readmitted (     ) should be still able to get a significant effect in 
terms of higher quality and, in turn, lower readmission rates even without providing 
necessarily for the optimal readmission policy (      ) or for the policy implementation 
discussed (     
 
 
). Therefore, at least for those medical sectors where the readmission 
probability strictly depends on quality, the theoretical results underlined in this paper and the 
associated policy recommendations represent certainly a valid contribution for both scholars 
and policy makers. 
 
5. Conclusions 
Inspired by some recent healthcare policies in OECD countries, in this paper we have 
studied the incentives for hospitals to provide quality and cost-reducing effort under different 
payment regimes, either a retrospective global budgeting or a prospective payment system. In 
particular, we have conducted our analysis within the spatial Hotelling framework where two 
hospitals compete in quality to attract a larger demand in the market for medical treatment. 
Differently from the existing literature, we focused on the role played by the readmission 
policy in driving providers’ behaviour and, in turn, in leading to the equilibrium quality. 
In our analysis we found that the propulsive role of competition provided by a 
prospective system might not be enough to guarantee unconditionally a higher equilibrium 
quality respect to a retrospective system. In particular, as long as the probability of 
readmission depends on the quality of treatment and hospitals receive a full payment for 
patients readmitted, a prospective payment system might even induce a reduction in quality 
and, in turn, an increase in readmission probability. Therefore, in the final part of the paper 
we have explored the impact of different readmission policies with the aim of adjusting this 
counter-incentive. This led us to the central result of our study, if the prospective payment 
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system is adjusted by a different payment for patients readmitted, it could be able to foster a 
higher hospital quality through the competition channel. Thus, the main implication of the 
paper is that those countries providing a full payment for patients readmitted in the context of 
a DRG-based PPS should be able to promote a higher quality and, in turn, lower readmission 
rates by partially discharging the risk of readmission to providers. 
Looking at the recent experience of those countries introducing severe limitation on the 
readmission payment (e.g. the US, Germany, the UK), once the pattern of readmission rates 
will be available, further empirical investigations will be able to test the role played by 
different readmission policies. Interestingly, the choice made by some countries of stopping 
entirely the payment for patients readmitted might not be the optimal solution according to 
our discussion, potentially inducing hospitals to avoid somehow to readmit those patients 
requiring a new treatment. Indeed, the readmission policy suggested in the final part of the 
paper should still be able to promote a higher healthcare quality, eliminating the scope for 
hospitals to make rationing. 
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